`F-18 Fluorothymidine ([18F]FLT) PET Imaging for Early Evaluation of Response to Chemoradiation Therapy in Patients With Cervical Cancer

Inclusion Criteria:

- Ability to understand and willingness to sign a written informed consent document.

- Histologically confirmed stage IB2, IIA, IIB, IIIB, and IVA squamous cell carcinoma
of the cervix.

- Scheduled to receive chemo-radiation for oncologic treatment.

- Karnofsky of at least 60 at time of screening

- Life expectancy of at least 6 months.

- Leukocytes at least 3,000/microL

- absolute neutrophil count at least 1,500/microL

- platelets at least 100,000/microL

- total bilirubin at maximum 1.0 mg/dL (UIHC limit of normal)

- either ALT or AST less than 2.5 times the upper limit of normal

- creatinine less than 1.5 times the upper limit of normal

- non-pregnant, non-nursing, willing to use contraception

Exclusion Criteria:

- oncology research protocol requiring full pelvic radiation (i.e., 4-field box
technique) or experimental chemotherapy

- uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
the study requirements.

- subjects taking nucleoside analog medications such as those used as antiretroviral
agents.

- patients who have undergone hysterectomy or will have a hysterectomy as part of their
cancer therapy.